Trifarotene for Acne: How It Compares to Older Retinoids

Trifarotene is a topical retinoid approved for acne that works differently from older options like tretinoin and adapalene. Classified as a fourth-generation retinoid, it selectively targets one specific receptor subtype in the skin, which is why it was the first new retinoid molecule approved for acne in over two decades. Its standout feature, and the reason dermatologists have paid close attention to it, is that it was studied and approved for use on both the face and the trunk, filling a gap that older topical retinoids never formally addressed.

What Makes Trifarotene Different From Older Retinoids

All topical retinoids work through nuclear receptors called retinoic acid receptors, but there are three subtypes of these receptors in the body: alpha, beta, and gamma. Older retinoids like tretinoin and adapalene activate more than one subtype, which is partly why they can cause irritation in tissues beyond the skin. Trifarotene was designed to be highly selective for the gamma subtype, with more than 20-fold selectivity over alpha and beta.¹ The gamma receptor happens to be the most abundant subtype in the epidermis, so targeting it specifically means trifarotene exerts more focused, skin-specific effects.²

This selectivity also has implications at the gene-expression level. A transcriptomics study found that trifarotene modulates a unique set of 67 genes primarily involved in cellular migration, inflammation, and extracellular matrix reorganization. It appeared to reverse many of the biological pathways associated with acne lesions, including downregulating inflammatory signals, immune cell trafficking, and collagen degradation pathways.³ In plain terms, it does not just unclog pores the way older retinoids do. It also dials down the inflammatory and tissue-remodeling processes that contribute to acne scarring and discoloration.

How Well It Works for Facial and Truncal Acne

Trifarotene was approved in the United States in 2019 for acne vulgaris in patients nine years and older, based on two identical phase 3 trials involving about 2,420 patients total. Those trials showed that trifarotene cream significantly reduced both inflammatory and noninflammatory lesion counts on the face and trunk compared to vehicle, with improvements visible as early as two weeks on the face and four weeks on the chest, shoulders, and back.⁴

The trunk part is worth emphasizing. Truncal acne, the breakouts that appear on the back, shoulders, and chest, affects a large percentage of people with facial acne but has historically been undertreated. Most topical retinoids were studied only on the face, so their use on the body was off-label and inconsistent. Trifarotene was the first topical retinoid to include truncal acne as a formal study endpoint, which gave clinicians an evidence base they previously lacked. A pooled analysis of adolescent patients ages 12 to 17 confirmed the drug was effective and well tolerated on both the face and trunk in that age group.⁵

Longer-term data paint a clearer picture of what to expect timeline-wise. In a 52-week study, facial success rates (based on investigator global assessment) were about 27% at week 12 but climbed to roughly 65% by week 52. Truncal success rates followed a similar trajectory, reaching about 67% at the one-year mark.⁶ This progressive improvement is typical of retinoids generally. They are not fast-acting spot treatments. You often need to push through an initial adjustment period of a few months before the full benefit becomes apparent.

Tolerability and Side Effects

The side effect profile of trifarotene follows the familiar retinoid pattern of local skin irritation: dryness, peeling, redness, and sometimes a stinging or burning sensation. In the long-term study, treatment-related adverse events were reported in about 13% of patients, and none were serious. Most of these reactions were skin-related and occurred during the first three months. Severe signs or symptoms were uncommon, reported by roughly 2% to 7% of patients on the face and 3% to 5% on the trunk.⁷

Irritation on the face peaked during the first week of treatment and then decreased. On the trunk, irritation took a bit longer to peak, around weeks two to four, before settling down. This is useful to know because many people abandon retinoids in the first couple of weeks when irritation is at its worst, not realizing the skin is adapting. Starting with every-other-night application and gradually increasing frequency is a common strategy, though the specific approach should be discussed with a prescriber.

One area where trifarotene’s receptor selectivity pays dividends is systemic absorption. In a pharmacokinetic study, after 29 daily applications of the standard 50 microgram-per-gram cream, blood levels of trifarotene were detectable in only about 37% of patients, and the concentrations were extremely low, in the single-digit picograms-per-milliliter range.⁸ For context, a picogram is one trillionth of a gram. These vanishingly small amounts suggest that even when the cream is applied over large body surface areas like the entire trunk, systemic exposure stays minimal. This matters because systemic retinoid effects, the kind associated with oral isotretinoin, including birth defect risk and liver concerns, are driven by higher blood concentrations that topical trifarotene simply does not reach.

Benefits for Post-Inflammatory Hyperpigmentation

For people with darker skin tones, acne itself is often only half the problem. The dark spots left behind after a breakout clears, known as post-inflammatory hyperpigmentation, can linger for months or years and are often more distressing than the acne itself. Trifarotene has shown promise in addressing this. A six-month phase 4 study found that trifarotene cream, paired with an appropriate skincare routine including sun protection, produced a better reduction in a validated hyperpigmentation scoring system compared to vehicle alone. The improvement was statistically significant and was observed across all skin phototypes.⁹

Beyond the clinical measurements, qualitative data from exit interviews in a related study found that all participants in the trifarotene group reported improvement in their hyperpigmentation by week 24, compared to about 83% in the vehicle-only group. More striking, over 90% of the trifarotene users said the change was meaningful to their emotional functioning, personal care routines, and social lives.¹⁰ The psychological burden of post-inflammatory hyperpigmentation is real and often underappreciated in clinical discussions, so evidence that a treatment not only clears active acne but also helps fade the marks it leaves behind is genuinely useful.

Reducing the Risk of Acne Scars

Acne scarring is permanent in a way that hyperpigmentation is not, and it remains one of the most feared consequences of moderate-to-severe breakouts. The mechanism behind trifarotene’s potential to reduce scarring connects back to its gene-expression effects. As mentioned, the drug downregulates pro-fibrotic pathways and collagen degradation while promoting extracellular matrix reorganization.¹¹ In practical terms, topical retinoids can stimulate the skin’s fibroblasts to increase collagen production and can thicken the epidermis, both of which work against the tissue destruction that creates pitted or atrophic scars.

A phase 4 controlled study specifically examined trifarotene’s effect on atrophic scarring and found that it reduced the risk of developing new acne scars. This is a prevention claim, not a reversal claim. Once deep scars have formed, they typically need procedural interventions like laser resurfacing or microneedling. But using trifarotene early and consistently during active acne may reduce the number of scars that form in the first place, which is arguably the more important clinical goal.

Using Trifarotene With Other Acne Treatments

Trifarotene does not have to work alone. Advisory guidance from dermatology panels suggests combining it with other topical or oral treatments depending on acne severity. For moderate-to-severe cases, pairing trifarotene with an oral antibiotic like doxycycline can enhance efficacy. Clinical evidence from the DUAL study showed that the combination of trifarotene plus oral doxycycline reduced lesion counts more effectively than vehicle plus placebo in patients with severe facial acne.¹²

Trifarotene can also be combined with benzoyl peroxide or azelaic acid for patients who need more than one topical agent. The practical challenge with layering multiple topicals is cumulative irritation. Dryness and peeling from a retinoid can be amplified by benzoyl peroxide, so the standard advice is to use the products at different times of day when possible. Trifarotene is typically applied in the evening, which leaves room for benzoyl peroxide or another active in the morning. Letting the skin adjust to one product before introducing a second can also reduce the chances of an irritation flare that prompts someone to abandon the regimen entirely.

Once the oral antibiotic has done its job, typically over a course of several weeks, trifarotene can continue as a maintenance therapy. This is an important distinction from many acne treatments. The long-term safety data supporting up to 52 weeks of continuous use, combined with its low systemic absorption, make it a viable option for ongoing prevention of new breakouts rather than just a short-term fix.¹³

Potential Uses Beyond Acne

Because trifarotene’s mechanism of action involves modulating skin-cell turnover and reducing inflammation in ways that extend beyond just targeting acne lesions, researchers have explored its potential in other dermatological conditions. The FDA granted trifarotene orphan drug designation for the treatment of congenital ichthyosis, a group of rare genetic disorders characterized by severely dry, thickened, and scaly skin.¹⁴ Retinoids have long been used in ichthyosis management, but the systemic versions carry significant side effects over the long term. A topical option with minimal blood absorption could offer a meaningful improvement in quality of life for patients with these conditions.

Photoaging is another area of early interest. An animal study found that trifarotene significantly reduced UV-induced skin aging in mouse tissue, apparently by lowering oxidative stress, reducing inflammatory signals, and inhibiting the breakdown of collagen while also reducing melanin deposition.¹⁵ This is preclinical work in mice, so extrapolating directly to human anti-aging claims would be premature. But given that tretinoin has long been the gold standard topical retinoid for photodamaged skin, the question of whether a more targeted, gamma-selective retinoid could deliver similar or better cosmetic benefits with less irritation is one that dermatologists and cosmetic chemists are watching closely.

Practical Tips for Getting Started

If you have been prescribed trifarotene or are discussing it with your dermatologist, a few practical points are worth keeping in mind. The approved formulation is a 0.005% cream (50 micrograms per gram), applied once daily in the evening to clean, dry skin. Unlike some older retinoids that came in gels or solutions with alcohol bases that could sting or dry out the skin more aggressively, the cream vehicle is generally better tolerated on large surface areas like the chest and back.

Sun protection is not optional. All retinoids increase photosensitivity by accelerating skin-cell turnover and thinning the outermost protective layer of dead cells. Applying a broad-spectrum sunscreen every morning is standard advice with any retinoid, but it becomes especially important when you are treating the trunk as well as the face, since the shoulders and upper back get more incidental sun exposure than many people realize.

Expect the first few weeks to feel counterintuitive. Your skin may actually look worse before it looks better, a phenomenon sometimes called the “retinoid purge” where accelerated cell turnover brings pre-existing microcomedones to the surface. Combined with the dryness and peeling that peak early, this phase can be discouraging. The long-term data showing that success rates roughly doubled between week 12 and week 52 should provide some reassurance that patience pays off. A bland, fragrance-free moisturizer applied after the trifarotene has absorbed, usually about 20 to 30 minutes after application, can help manage the dryness without interfering with the drug’s absorption.

Who Might Not Be a Good Candidate

Like all topical retinoids, trifarotene is contraindicated in pregnancy. Even though systemic absorption is minimal, the retinoid class as a whole carries teratogenic risk, and no topical retinoid has been shown to be safe during pregnancy. Women of childbearing potential should use effective contraception while on the drug. Breastfeeding guidance is less clear-cut, but most prescribers err on the side of caution and recommend avoiding retinoids while nursing.

People with eczema or other conditions that compromise the skin barrier should approach with extra caution. Retinoids can worsen barrier dysfunction, and applying them to skin that is already inflamed or cracked can trigger significant irritation. The same goes for anyone using other potentially irritating products like high-concentration glycolic acid, salicylic acid peels, or prescription-strength vitamin C serums. Layering too many active ingredients at once is one of the most common reasons people experience intolerable side effects from retinoids and then blame the retinoid rather than the regimen.

Children under nine years old fall outside the approved age range. For adolescents between 9 and 11, the prescribing decision typically weighs the severity of acne against the child’s ability to tolerate treatment and follow a consistent skincare routine, including sun protection. The pooled adolescent analysis supports use in the 12-to-17 age range with a side effect profile that did not differ meaningfully from adults.¹⁶

How Trifarotene Fits Into the Broader Retinoid Landscape

Topical retinoids have been a mainstay of acne treatment for over 50 years, starting with tretinoin in the 1960s and progressing through adapalene and tazarotene. Each generation brought refinements in tolerability or potency, but the fundamental approach of activating retinoic acid receptors to normalize skin-cell turnover and reduce inflammation stayed the same. Trifarotene’s receptor selectivity represents a genuine shift in approach rather than just an incremental tweak. By focusing specifically on the gamma receptor, the most prevalent subtype in skin, it was designed to concentrate its effects where they matter for dermatology while leaving other receptor subtypes, more relevant to systemic processes, largely alone.¹⁷

Whether this translates into a meaningfully better clinical experience than adapalene for the average patient is still being worked out. Head-to-head comparative trials between trifarotene and other topical retinoids are limited, and much of the real-world comparison happens informally in dermatology offices. What the existing evidence supports is that trifarotene is effective for both facial and truncal acne, tolerable over long-term use, and carries additional benefits for hyperpigmentation and possibly scar prevention. For someone whose acne primarily affects the trunk, or whose skin reacts poorly to older retinoids, it represents a genuinely useful addition to the treatment toolkit rather than just another molecule in an already crowded category.